PI change on the agenda

TGA issues safety reminder and advises of updates to infliximab product information Changes to the product information of Remicade (infliximab) have been flagged by the TGA in a recent newsletter, in which it also said there had been an increase in adverse event reports linked to lupus-like symptoms. In its December 2018 Medicines Safety Update,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacists take on crucial new service
Next Health Care Homes program extended